5751-17-7Relevant articles and documents
Molecular Recognition of Creatinine
Buehlmann, Philippe,Badertscher, Martin,Simon, Wilhelm
, p. 595 - 598 (1993)
A host-guest system involving derivatives of 2-amino-4(3H)-pyrimidone and creatinine was developed. 1H NMR and 13C NMR experiments give evidence of complex formation.A geometry optimazation with Gaussian 88 suggests a complex structure in which the 5-membered and the 6-membered heteroring are connected by one long and two shorter hydrogen bonds.The hosts described strongly enhance the extraction of creatinine from its aqueous solution into CH2Cl2 and CDCl3.As the creatinine concentration in the organic solvents may be determined by measuring the changes in the UV spectrum of the hosts upon complexation, derivatives of 2-amino-4(3H)-pyrimidone may eventually be used in optical creatinine sensors.
DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
-
Paragraph 0500, (2014/01/08)
The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.
DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
-
Page/Page column 43, (2012/09/11)
The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.